Publication
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (10)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 10
- cancerCholangiocarcinomacivic_curation1.00
- drugErlotinibcivic_curation1.00
- drugPazopanibcivic_curation1.00
- drugPonatinibcivic_curation1.00
- geneERRFI1civic_curation1.00
- geneOGAcivic_curation1.00
- geneTACC3civic_curation1.00
- variantERRFI1 E384*civic_curation1.00
- variantOGA Fusioncivic_curation1.00
- variantTACC3 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24550739
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERRFI1 E384*2 | ||||||||
| Erlotinib | Cholangiocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1724An ERRFI1 (E384X) was detected in a patient with metastatic, recurrent/refractory cholangiocarcinoma (allelic fraction 11%) without any mutations or amplifications in other EGFR signaling members such… (full text at CIViC) PMID 24550739 · Borad et al., 2014 · Open in CIViC | civic |
| 〃 | Cholangiocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | rejected | EID5869A patient with cholangiocarcinoma who has initially undergone surgical resection progressed on gemcitabine and cisplatin. He subsequently received pegylated hyaluroniade (PEGPH20) in an investigationa… (full text at CIViC) PMID 24550739 · Borad et al., 2014 · Open in CIViC | civic |
| OGA Fusion1 | ||||||||
| Ponatinib | Cholangiocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID295In a single patient with this fusion in intrahepatic cholangiocarcinoma. Ponatinib treatment resulted in necrosis and shrinkage of the primary and metastatic sites and overall stable disease. However,… (full text at CIViC) PMID 24550739 · Borad et al., 2014 · Open in CIViC | civic |
| TACC3 Fusion1 | ||||||||
| Pazopanib + PonatinibSequential | Cholangiocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID296In a 43 year old female patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor tumor shrinkage. This fusion is also shown to be recurren… (full text at CIViC) PMID 24550739 · Borad et al., 2014 · Open in CIViC | civic |